## Targeted Access to Community Knowledge, Linkage to treatment and Education for HIV/HCV in people of color (TACKLE HIV/HCV in people of color)

Trisha Melhado MPH Senior Research Scientist, UTHSA

Vittoria Criss MS Hepatitis C Prevention Coordinator, DSHS



### TACKLE HIV/HCV in people of color

- Background
  - TACKLE HIV/HCV
  - Department of State Health Services (DSHS)
- TACKLE HIV/HCV goals and partnerships
- Select activities
  - Year 1 planning
  - HIV/HCV ECHO
  - Sentential surveillance
  - Community events
- Sustainability and next steps



# **TACKLE HIV/HCV Background**



## HIV/HCV co-infection

- Approx. 30% of people living with HIV (PLWHIV) in the US are co-infected with HCV
- Co-infected individuals develop histological and clinical features of HCV liver disease more rapidly than those with HCV alone
- Patients with HIV infection are less likely to clear HCV and more likely to develop chronic infection
- Tolerance of antiretroviral agents is poorer in patients with chronic HCV with a greater risk of hepatotoxicity
- Clearance of HCV has been associated with regression of liver fibrosis

Cooper et al. Can J Infet Dis 2001:12 (3): 157-163 Soriano, V. et al. Antiviral Research 2010 85(1): 303 - 315



## TACKLE HIV/HCV in people of color

- Targeted Access to Community Knowledge, Linkage to treatment and Education for HIV/HCV in people of color
- A HRSA funded Special Project of National Significance (SPNS)
- An area network of Ryan White HIV/AIDS program funded clinics in implementing comprehensive, effective HCV screening, care and treatment systems in people living with HIV including people of color across South Texas



# Department of State Health Services (DSHS)



## DSHS

- DSHS Hepatitis C Team
  - Prevention
  - Surveillance
- Partnership with TACKLE
  - Enhance acute and chronic hepatitis C surveillance
  - Design and implement sentinel surveillance system
  - Create data collection tools
  - Serve as SMEs on hepatitis C surveillance and data reporting




# TACKLE HIV/HCV Goals and Partnerships



### **PROGRAM GOALS**

GOAL 1 - Establishment of a model of integration of HCV services into HIV services and support of substance use disorder/mental health services	GOAL 2 - Provision of provider support including non specialist provider support for HIV/HCV co-infection management and treatment	GOAL 3 - Education about and screening for HIV/HCV in communities predominantly composed of people of color	GOAL 4 - Sentinel surveillance for acute and chronic HCV in people living with HIV (including people of color)
Clinic HIV/HCV care model Fibroscan	(AETC) National HIV/HCV curriculum dissemination	Community education and screening events	Enhance TX DSHS acute HCV surveillance Pilot chronic
SUD/Depression screening and linkage to support/treatment) Pilot opioid overdose program	ECHO (Extension of Community Health Outcomes) model	HIV/HCV Education App	HCV sentinel surveillance program Pilot data to care

**EVALUATION – FOCUS ON PROCESS EVALUATION (vs. IMPACT/OUTCOME EVALUATION)** 



# **TACKLE HIV/HCV Activities**



### Year 1 – planning and project infrastructure

- Established HIV/HCV ECHO, create a promotional video + obtain MOC/CME accreditation, train staff and partners
- Constructed websites for TACKLE and ECHO
- Detailed needs assessment, project implementation + local evaluation plans
- Produced protocols/forms and databases to unify project implementation with partners' input
  - ECHO protocol, case presentation and recommendations forms
  - Bidirectional referral processes: clinic  $\leftarrow \rightarrow$  SUD/MH
  - Fibroscan clinical reporting guidelines and pricing
  - HIV/HCV drug interaction and side effects + DAA drug access protocol
  - Reporting of acute HCV
  - Distribution of AETC HIV/HCV Co-infection Curriculum
  - HIV/HCV educational app
  - Surveillance Clinic and community





### PROSPECTIVE HIV/HCV CARE CONTINUUM DATA COLLECTION FORM

MEDICAL RECORD NU	MBER:												
DATE OF CLINIC VISITS	FOR HCV TREAT	ИENT							Т	CLINIC	NAME:		
1	(Patient age:	) 5	5		(P	atient	age:	J		🗆 SAA	νF		
2	– (Patient age:	) 6	5		(P	atient	age:	J			stal Bend Wel		lingen
3	– (Patient age:	)7	7		(P	atient	age:	J		U Val	ey AIDS Coun	-	-
4	(Patient age:	) 8	3		(P	(Patient age: )			☐ FFA ☐ AAF				
DEMOGRAPHICS									<u> </u>				
PATIENT NAME Last	First		Мі	1	DATE (	of Bir.	TH (m	m/dd/y	гууу)				
HOME ADDRESS City State Zip COUNTY OF RESIDENCE COUNTRY OF BIRTH						)							
GENDER ETHNICITY Male Female MTF FTM Hispanic or Latino/a Transgender (unspecified) Not Hispanic or Latino Other (please specify: ) Unknown						White/ Asian Native		sian an or	Amer Black Pacific Is	ican Indian/ or African-A lander	merio		
PATIENT INFORMAT	ION												
RYAN WHITE STATUS RW eligible/client Not RW eligible/client								ivate		edicare	Medicai	d 🗆	CareLink
INJECTION DRUG USE HISTORY   Never used Current user Used but NOT current user  Date reported:						/ Yes		No					
NONINJECTION DRUG USE HISTORY  Never used Current user Used but NOT current user Date reported:						Mariju	Jana		aine/o	crack 🗖	ction drug ( Methamphe		e (Meth)
HISTORY OF MENTAL HEALTH DISORDER If yes, ment				ession		🗆 Ar	er diag nxiety d ther (ple	lisord	er				

нсу								
SYMPTOMATIC?								
1 No Unknown								
Yes - if yes, symptoms (check all that apply):				Onse	t of symptoms (mm/dd/yyyy)			
🗆 Diarrhea 🔲 Dark urine 🗆 Abdominal pain								
	Fatigue	🗌 Othe	r:					
2 No Unknown			uria. 🗖 elas atasla	o	t of symptoms (mm/dd/vvvv)			
Yes - if yes, symptoms (check all that apply):			exia 🔲 Clay stools urine 🗆 Abdominal pain	Unse	t of symptoms (mm/ad/yyyy)			
	Diarmei     Fatigue							
			·					
REASONS FOR TESTING (check all that apply)								
1 Symptoms of acute hepatitis Exposure to case HIV positive, initial screening for HCV Unknown								
Evaluation of liver enzymes Prenatal sc			e, routine screening for HCV	🗆 Oti	her:			
2 Symptoms of acute hepatitis D Exposure t					known			
Evaluation of liver enzymes Prenatal sc	reening 🗆	HIV positiv	e, routine screening for HCV	🗌 Ot	her:			
SCREENING								
EVER SCREENED FOR HCV	□ Yes (If yes	, date mos	t recently screened for HCV:		)			
DIAGNOSIS								
HCV INFECTION TYPE			DATE OF DIAGN	IOSIS				
1 Probable Chronic* Confirmed Chro	nic* 🗆 Acut	e	1					
2  Probable Chronic*  Confirmed Chro	nic* 🗆 Acut	e	2					
*Definitions:								
PROBABLE CHRONIC HEPATITIS C: Chron			-	d rele	vant laboratory			
information indicative of acute infection		-						
CONFIRMED CHRONIC HEPATITIS C: Chro information indicative of acute infection			-	ina re	levant laboratory			
1	2	ne nem jro		3				
Anti-HCV positive     NAT for HC	V RNA positiv	/e	No report of test conversion	on (do	cumented negative anti-HCV,			
(including ge	-				ollowed within 12 months by			
HCV antige	en positive		a positive result)					
TREATMENT								
EVER TREATED FOR HCV		If previou	usly treated, HCV treatme	nt ou	tcome:			
Treatment naïve Previously treated w	ith DAA	Cure	d 🛛 Not	cured				
Previously treated no DAA		Cure Cure	d and reinfected 🛛 🛛 Unkr	nown				
PRESCRIBED TREATMENT					Date treatment prescribed:			
1 🗆 No 🗆 Yes, non-DAA 🛛 Yes, DAA (name	of DAA prescr	ibed:	) Unknov	wn	1			
2 🗆 No 🔲 Yes, non-DAA 🛛 Yes, DAA (name	of DAA prescr	ibed:	) Unknov	wn	2			
TREATMENT DELAYED OR LOST TO CARE?	-		atment delayed or lost to	care:	· · · · · · · · · · · · · · · · · · ·			
1 🗆 No 🗖 Yes					ent 🗌 Incarcerated 🔲 Pregnant			
	. – .	-	nce) 🗌 Other:					
2 No Yes 2 Died Moved Refused/hesitant to start treatment Incarcerated Pregnant								
	Paper v	vork (insura	nce) 🗌 Other:					
Date HCV treatment started: Date HCV treatm	ent complete	ed: SVR fo	llowing treatment?					
11		1 🗆	No 🔲 Yes (if yes, date of treat	ment o	ompletion SVR: )			
2 2								
Documented SVR12?								
1 No Yes (If yes, date SVR12 achieved:			}					
2 No Yes (If yes, date 5VR12 achieved:								
2 No Yes (If yes, date 5VR12 achieved:			)					

RISK FACTOR INFORMATION			
Have the person ever had any of the following risk exposures?	Yes	No	Unknown
Received a blood transfusion prior to 1992			
Received an organ transplant prior to 1992			
Received clotting factor concentrates prior to 1987			
Long-term hemodialysis			
One or more male sex partners			
How many?			
One or more female sex partners			
How many?			
Treated for a sexually-transmitted disease			
Date of most recent treatment:			
Contact with person who had hepatitis			
Employment in a medical/dental field involving use of universal precautions (e.g.			
gloves) because of potential of exposure to human blood			
Employment as a public safety worker involving use of universal precautions (e.g.			
gloves) because of potential of exposure to human blood			
Accidental stick or puncture with a needle or other object contaminated with blood			
Date of most recent event:			
Injected drugs or cosmetic products (i.e. Botox) not prescribed by a doctor			
Date of most recent event:			
Used non-injected street drugs (i.e., intranasal drug)			
Date of most recent event:			
Injected drugs prescribed by a doctor (i.e., insulin, blood thinning medication)			
Date of most recent event:			
Finger stick at home			
Date of most recent event:			
Outpatient procedure, specifically colonoscopy, endoscopy, or colposcopy			
Date of most recent procedure:			
Dental work or oral surgery in another country			
Date of most recent treatment:			
Location:			
Surgery other than dental work or oral surgery in another country			
Date of most recent treatment:			
Location:			
Manicure or pedicure in another country			
Date of most recent event:			
Location:			
Body piercing			
Piercing locations (check all that apply):			
Commercial parlor Jail/Prison At home Other (specify:	)		
Tattoo			
Tattooing locations (check all that apply):			
Commercial parlor Jail/Prison At home Other (specify:	)		
Acupuncture treatment			
Date of most recent treatment:			
Incarceration			
Date of most recent release:			
Length of incarceration:			





### Acute Hepatitis C Provider Reporting Procedure


 Determine through Provider Reporting Checklist if required variables for reporting are present in medical record.

	Acute Hepatitis C Reporting Checklist
Acute (	Case Clinical Criteria Description
An acu	te illness with discrete onset of symptoms consistent with acute viral hepatitis (e.g., fever,
headac	he, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain),
AND Ja	undice, OR A peak elevated serum alanine aminotransferase (ALT) level >200 IU/L during the
period	of acute illness
	o history of Hepatitis C infection or diagnosis of chronic Hepatitis C.
	tory Criteria: At least ONE of the following present
	A positive test for antibodies to hepatitis C virus (anti-HCV)
	Nucleic acid test (NAT) or PCR test for HCV RNA positive (including qualitative, quantitative
	or genotype testing)
	A positive test indicating presence of hepatitis C viral antigen (HCV antigen)
	oms: At least ONE of the following present
_	Fever
_	Headache
	Malaise
	Anorexia
	Nausea
	Vomiting
	Diarrhea Abdumia di Bala
	Abdominal Pain
	aundice OR ALT
	Jaundice
	Elevated ALT
	ctors: At least ONE of the following present Ever injected illicit drugs
	Ever injected micit drugs Ever incarcerated for longer than 6 months
	History of HIV or STD
	Received clotting factor before 1987
	Ever been on long term hemodialysis
	Born to HCV positive mother
	Known exposure to person with HCV, such as
	eedle stick injury in healthcare setting, unregulated tattoo or sharing personal items
	contaminated with infectious blood
2. Fill c	ut an Infectious Disease Report Form, which can be found online at this link:
	s://www.dshs.state.tx.us/IDCU/investigation/Reporting-forms/EPI-2-2017.pdf

- 3. Attach patient's medical record including variables for reporting indicated on checklist.
- 4. Contact local or regional health department to determine preferred method of reporting (fax, mail, electronic medical record)

### For a list of Disease Reporting Contacts please visit this link:

https://dshs.texas.gov/IDCU/investigation/conditions/Disease-Reporting-Contacts.aspx





### UT Health San Antonio ECHO (Extension for Community Healthcare Outcomes)



# ECHO Introductory video (90 s)

# UTHSA ECHO video



Copyright © ECHO Institute

## UT Health San Antonio HIV/HCV ECHO

N ECHO sessions	39
N cases presented	46
Total number of attendees	947
Average number of attendees per session	24
Number of PLWHIV reached	3,226
Number of HIV/HCV clients reached	82





# **HIV/HCV Surveillance**



## **HCV Case Definition**


HCV INFECTION TYPE		DATE OF DIAGNOSIS
1 🗆 Probable Chronic* 🔲 (	Confirmed Chronic* 🗖 Acute	1
2  Probable Chronic*	Confirmed Chronic* 🗖 Acute	2
*Definitions:		
PROBABLE CHRONIC HE	PATITIS C: Chronic condition with no	available evidence of clinical and relevant laboratory
information indicative of	f acute infection and with items from	n columns 1 and 3
CONFIRMED CHRONIC	HEPATITIS C: Chronic condition with I	no available evidence of clinical and relevant laboratory
information indicative of	f acute infection and at least one iter	m from columns 2 and 3
1	2	3
<ul> <li>Anti-HCV positive</li> </ul>	<ul> <li>NAT for HCV RNA positive</li> </ul>	<ul> <li>No report of test conversion (documented negative anti-HCV,</li> </ul>
	(including genotype)	HCV NAT, or HCV antigen result followed within 12 months by
	HCV antigen positive	a positive result)



Overview of TACKLE clients from five clinical sites						
Screened for HCV	2,833					
HCV Ab+	216					
Probable HCV	40					
Confirmed HIV/HCV coinfection	127					
SUD/MH referral	30					



### TACKLE HCV Care Cascade\*



\*n=25 loss to follow-up, patient moved, incarceration, pregnancy, death



# **Community Events**



TACKLE HIV/HCV C	ommunity Events Summary
------------------	-------------------------

Number of events	4
People in attendance (est.)	1,100+
N screened for HIV/ HCV/ Syphilis	91/ 81/ 89
Flyers distributed	220
N educated with app	123



# App

# Flyer

### **UT Health San Antonio**



### What is Hepatitis C?

Hepatitis C virus (HCV) is a liver infection. HCV infection causes few symptoms for many years.

Most people with HCV have no idea that they have it.

It is important to know, because it can seriously hurt your liver.

There is a cure for HCV and most people can be cured.

Back Next

### **UT Health San Antonio**

### **QUICK QUESTION**

What part of your body can Hepatitis hurt?



### TREATHEP C BEATHEP C

Targeted Access to Community Knowledge, Linkage to treatment and Education for HIV/HCV (TACKLE HIV/HCV)

### Vhat you should know about HIV and Hepatitis C

#### WHAT IS HIV?

» HIV is a virus.

» HIV attacks immune cells in the body, so it can't fight infection.

#### WHAT IS HEPATITIS C?

- » Hepatitis C is a viral infection.
- » Hepatitis C virus (HCV) damages your liver. Your liver: - helps your body use the food you eat
- filters your blood
- helps blood clot
- fights infections

#### WHAT IS HIV/HCV CO-INFECTION?

- » HIV/HCV co-infection is when a person has both HIV and HCV infection at the same time.
- » Both HIV and HCV are viruses and are transmitted in similar ways.
- » If you have both HIV and HCV infection at the same time, you are more likely to get liver damage from HCV.

#### WHY SHOULD I GET TESTED FOR HIV AND HCV?

- » The only way you know for sure whether you have HIV and/or HCV is to get tested.
- » If you get tested, you can get treated.
- » There is no cure for HIV infection but people on HIV treatment can live a healthy, normal life.
- » There is a cure for HCV infection.

#### WHERE CAN I GET TESTED FOR HIV AND HCV?

- » Your primary care provider can test you for HIV and HCV.
- » Search for a testing site near you by accessing CDC's online locator: gettested.cdc.gov
- » TACKLE HIV/HCV offers free HIV and HCV screening at community screening events. For details, visit online: uthscsa.edu/tackle/events

#### HOW ARE HIV AND HCV TREATED?


- » There are very effective drugs available today to treat both HIV and HCV infections.
- » HCV infection can be treated and cured in most cases with one pill a day for 8-12 weeks.
- » HIV infection can be treated in a lot of cases with one pill a day, but HIV treatment is life-long.



FOR MORE INFORMATION, VISIT: UTHSCSA.EDU/TACKLE OR CONTACT: TACKLEADMIN@UTHSCSA.EDU

Back

# Percent correct responses to teach back questions in app (N=123)





Date of Event (mm/dd/yyyy):

Name of Community Event:

Patient Information Patient Name:	Date of Birth (mm/dd/yyy	yy):	Linkage to service –
Home Address:			
Cell Phone:			Integrated model of
I hereby authorize TACKLE HIV/HCV Project to re	lease information to:		0
TACKLE HIV/HCV Clinical Site      Coastal Bend Wellness Foundation     San Antonio AIDS Foundation      Valley AIDS Council      FFACTS      AARC      PILLAR      CHCS      Texas Department of State Health Services	Clinic Name: Address: Clinic Phone (if known):		care
Texas Department of State Realth Services			
Hepatitis C Surveillance Team, TB/HIV/ST	D Epidemiology and Surveillance Branch	h	
Description of items to be released:			
1) Hepatitis C antibody results			
<ol> <li>Hepatitis C viral load/ RNA results</li> <li>Acute/ Chronic HCV Sentinel Surveillance</li> </ol>	e Case Report Form		
Purpose for use and/or disclosure: Linkage to HO	CV care and treatment		
<ul> <li>I understand this authorization will expire in</li> <li>I understand that the Texas Department of S regarding my hepatitis C status.</li> <li>I understand that the information used or dia may no longer be protected by federal or state</li> <li>I understand I have the right to revoke this a I must do so in writing and present my writter revocation will not apply to information that</li> <li>I understand that authorization for the use of</li> </ul>	itate Health Services may contact me fo isclosed by this authorization may be dis ate law. Inthorization at any time. I understand i en revocation to the agency's Privacy Of t has been already been released in resp	or additional information sclosed by the recipient and if I revoke this authorization, fficer. I understand the ponse to this authorization.	
Patient or Personal Representative Signature	Print Name	Date	
TACKLE HIV/HCV Staff Signature Page 1 of 1	Print Name	Date Version 2: 5/15/2019	
AUTORIZACIÓN PARA EL USO Y I	DIVULGACIÓN DE INFORMACIÓN DE SAI	LUD PROTEGIDA 18	
Nombre del Evento Comunitario:	Fecha del evento (m	nm/dd/aaaa):	UT
Información del Paciente			San Ar
Nombre del paciente:	Fecha de nacimiento (mr	m/dd/aaaa):	TACK



# TACKLE HIV/HCV Sustainability and Next Steps



## Sustainability

- Partners overwhelmingly agree about the positive impact of the HIV/HCV ECHO and plan on continued participation
- Sites find the project materials (ex. bidirectional referral processes, forms, protocols, bilingual materials ) helpful and plan to use them beyond the end of TACKLE
- A few sites will retain the community health worker (CHW) role since it positively impacted patient management
- When possible, partners will implement HIV/HCV screening and education community events



## **Next Steps**

- Provide Texas Department of State Health Services (TX DSHS) with a staff member to compile and clean their existing chronic HCV data
- Development of a mobile application to support HIV providers to treat HCV
- UT Health San Antonio South Central AETC HIV/HCV workshops
- Continue to offer UT Health San Antonio HIV/HCV ECHO as a resource to primary care providers who want to treat HIV/HCV coinfection
- Create an observational database of HIV/HCV coinfected patients



### **Contact/Interact with Us**

### TACKLE HIV/HCV Website:

www.uthscsa.edu/tackle

**UT Health San Antonio ECHO Website:** 

www.uthscsa.edu/echo



Find us on Facebook: @UTHealthSAECHO

For general inquiries about UT Health San Antonio ECHO: <u>echoinfo@uthscsa.edu</u>

Program Director/Principal Investigator - Wari Allison MD PhD allisonw@uthscsa.edu

Senior Research Scientist - Trisha Melhado MPH Melhado@uthscsa.edu

Hepatitis C Prevention Coordinator, DSHS - Vittoria Criss MS Vittoria.Criss1@dshs.texas.gov

